upfront and committed up to Us$1.875 B in milestones for rights to GUB014295, an early-stage potential best-in-class, long-acting amylin analog for the across the areas of respiratory, immunology, inflammation, and oncology. Other examples of with 3SBio, which included an astounding US$1.25 B upfront payment as well as up to US$4.8 B in milestones, for PD-1/VEGF bispecific antibody, SSGJ-707 as well as Takeda's US$11.4 B partnership with Innovent Biologics for two late-stage medicines, pipeline, RayzeBio, a Bristol-Myers Squibb company, rights to develop, manufacture and commercialize OncoACP3, a small molecule ligand with high affinity and specificity for acid phosphatase 3 (ACP3), a novel target in prostate cancer. A Phase I oncology asset also gained the attention of AbbVie in July, when it investigational asset, ISB 2001, developed using IGI's proprietary BEAT@ protein platform, for oncology and both cash and equity). Despite ongoing uncertainties in the industry, big pharma continued to show signs of Expanding its hematological portfolio, in March, return for access to promising and innovative assets. development and commercialization of sapablursen, and similarly investing in a rare cancer treatment, staggering US$1.65 B upfront as well as up to US$3.6 B to advance a new treatment for uveal melanoma. petrelintide, Zealand's amylin analog, as a standalone Roche's incretin asset, CT-388. An amylin agonist in the life sciences sector, the volume of licensing Roche-Zealand deal. AbbVie paid Gubra US$350 M